相关实验视频
Updated: Jul 13, 2025
07:23
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
6.0K
恩帕格利弗洛辛通过直接增加心脏子利用率来改善缺血/再输血期间的心脏能量
Dylan Chase1, Thomas R Eykyn1,2, Michael J Shattock1
1British Heart Foundation Centre of Research Excellence, King's College London, The Rayne Institute, 4th Floor, Lambeth Wing, St Thomas' Hospital, London SE1 7EH, UK.
Cardiovascular research
|October 11, 2023
概括
恩帕格利弗洛辛 (EMPA) 通过增加基利用率而不是葡萄糖,在缺血和再注射期间增强心脏功能. 这种新陈代谢转变改善了心脏能量,独立于基质的可用性.
科学领域:
- 心脏病学 心脏病学
- 代谢科学 代谢科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 恩帕格利弗洛辛 (EMPA) 是一种-葡萄糖共运输体2抑制剂,表现出超出血糖控制的心脏保护作用.
- 建议的机制包括增加心脏子供应,但对心脏代谢的直接影响尚不清楚.
研究的目的:
- 调查Empagliflozin (EMPA) 是否直接改变心脏类代谢,独立于基质供应.
- 确定EMPA在缺血-再输血期间对心脏功能和能量的影响.
主要方法:
- 兰登多夫老鼠心脏模型接受低流动性缺血/再输血.
- 使用31P NMR光谱测定心脏能量.
- 使用13C标记的葡萄糖和β-基酸 (βHb) 与2D 1H-13C HSQC NMR进行代谢流量分析.
主要成果:
- 在缺血/再输血期间,EMPA治疗改善了左心室压力,并保持了ATP和脂蛋白水平.
- EMPA将心脏代谢从葡萄糖转移到 (βHb) 的利用,这是通过改变13C纳入TCA循环中间体的证据.
- 没有观察到葡萄糖纳入乳酸或氨酸的变化,这表明了特定的基质偏好开关.
结论:
- 恩帕格利弗洛辛 (EMPA) 促进了基利用,而不是心脏中的葡萄糖氧化,在缺血和再注射期间增强功能和能量.
- 这种代谢切换发生的独立于基质的可用性,表明对心脏基质偏好的直接影响.
- 需要进一步的研究来阐明EMPA对心脏代谢的直接调节背后的精确机制.
关键词:
恩帕格利弗洛辛 (Empagliflozin) 是一种非常重要的药物.心脏衰竭是因为心脏衰竭.缺血症-再输血 缺血症-再输血孤立的心脏 孤立的心脏基子 基子 基子代谢过程中的代谢.SGLT2 抑制剂的使用.-葡萄糖运输体 2 运输体 2 运输体基质利用的使用情况.更多相关视频
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
192
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
192
01:26Heart Failure Drugs: Inotropic Agents
598
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
598
01:30Heart Failure V: Medical Management
10
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
10
01:25cAMP-dependent Protein Kinase Pathways
6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
441
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
441
01:24Glucagon-like Receptor Agonists
334
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
334